| | 股东身份 | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | | | 董事、监事、高 级管理人员 | 11,178,000 | 2.75% | IPO 前取得：11,178,000 股 | | 股东名称 邱培静 | | | | | | 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2024-065 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司董事减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事持股的基本情况 奥锐特药业股份有限公司（以下简称"公司"）董事邱培静女士于本次减持 计划实施前持有公司股份 11,178,000 股，占公司总股本的 2.75%，其所持有股 份来源于公司首次公开发行股票前取得的股份。 减持计划的实施结果情况 公司于 2024 年 8 月 20 日披露了《奥锐特药业股份有限公司关于部分董 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-064 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于"奥锐转债"预计满足转股价格修正条件的提 示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债 券》规定，本次触发转股价格修正条件的期间从 2024 年 11 月 18 日起算。截至 2024 年 12 月 6 日，奥锐特药业股份有限公司（以下简称"公司"）股票已有 10 个交易日的收盘价低于"奥锐转债"当期转股价格的 85%（即 21.45 元/股）。若 公司股票收盘价格在任意连续三十个交易日中至少有十五个交易日的收盘价低 于当期转股价格的 85%时，预计将触发"奥锐转债"转股价格向下修正条款。若 触发条款，公司将于触发条款当日召开董事会审议决定是否修正转股价格，并及 时履行信息披露义务。敬请广大投资者注意投资风险。 一、"奥锐转债"发行上市概况 经中国证券监督管理委员会《关于同意奥锐特药业股份有 ...

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2024-063 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 12 月 02 日(星期一) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.ss einfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 25 日(星期一) 至 11 月 29 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aurisco. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 奥锐特药业股份有限公司（以下简称"公司"）已于 2024 年 10 月 25 日发 布公司 2024 年第三季度报告，为便于广 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-062 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于为全资子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次担保情况概述 （一）本次担保基本情况 2024年11月19日，公司与中国工商银行股份有限公司扬州邗江支行（以下简 称"工商银行"）签署了《最高额保证合同》，同意公司为全资子公司扬州奥锐 特向工商银行申请的最高额综合授信（在2024年11月6日至2027年11月6日期间签 订的全部主合同）提供连带责任保证，担保额度为人民币4,000万元。本次担保 未提供反担保。 （二）本次担保事项履行的内部决策程序 2024年1月2日，公司第三届董事会第五次会议审议通过了《关于对外担保额 度预计的议案》。具体内容详见公司于2024年1月3日在《上海证券报》《中国证 被担保人名称：公司全资子公司扬州奥锐特药业有限公司（以下简称 "扬州奥锐特"） 本次担保金额：奥锐特药业股份有限公司（以下简称"公司"） ...

关于使用部分闲置募集资金进行现金管理进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：兴业银行股份有限公司台州临海支行（以下简称"兴 业银行"） 已履行的审议程序：奥锐特药业股份有限公司（以下简称"公司"或"奥 锐特"）于 2024 年 8 月 27 日召开第三届董事会第八次会议及第三届监事会第八 次会议分别审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同 意公司及子公司使用闲置募集资金不超过人民币 3 亿元进行现金管理，上述额度 可以滚动使用，自第三届董事会第八次会议审议通过之日起 12 个月内有效，并 授权公司管理层在上述额度内行使决策权，具体事项由公司财务部负责组织实施。 具体内容详见公司于 2024 年 8 月 29 日披露于上海证券交易所网站 （www.sse.com.cn）的《奥锐特药业股份有限公司关于使用部分闲置募集资金进 行现金管理的公告》（公告编号：2024-047）。 特别风险提示：尽管本次公司选择的现金管理产品属于保本型理财产品， 但金融市场受宏观经济、 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-060 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 单位：人民币万元 特此公告。 奥锐特药业股份有限公司董事会 2024 年 11 月 13 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 奥锐特药业股份有限公司（以下简称"公司"或"奥锐特"）于 2024 年 8 月 27 日召开第三届董事会第八次会议及第三届监事会第八次会议分别审议通过 了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司及子公司使用 闲置募集资金不超过人民币 3 亿元进行现金管理，上述额度可以滚动使用，自第 三届董事会第八次会议审议通过之日起 12 个月内有效，并授权公司管理层在上 述额度内行使决策权，具体事项由公司财务部负责组织实施。具体内容详见公司 于 2024 年 8 月 29 日披露于上海证券交易所网站（www.sse.com.cn）的《奥锐特 药业股份有限公司关于使用部分闲置募集资金进行现金管理的公告》（公告编号： 2024-047）。 2024 年 ...

Investment Rating - The report maintains a "Buy" rating for the company [3][4]. Core Views - The company shows improved profitability, with a revenue of 1.088 billion yuan for Q1-Q3 2024, representing a year-on-year growth of 17.97%. The net profit attributable to the parent company reached 284 million yuan, up 22.04% year-on-year. However, Q3 revenue saw a decline of 3.30% year-on-year, and net profit dropped by 30.33% due to high base effects from the previous year and financial costs [3][4]. - The gross margin for Q1-Q3 2024 was 58.22%, an increase of 2.58 percentage points year-on-year, with Q3 gross margin at 60.68%, reflecting continuous improvement driven by high-margin product sales [3]. - The company is focusing on enhancing its specialty raw materials and formulation business, with significant progress in its peptide and oligonucleotide platform capabilities. The company is also expanding its international marketing system [3][4]. Financial Summary - For 2024E, the company forecasts revenue of 1.566 billion yuan, with a year-on-year growth of 24.1%. The net profit is projected to be 393 million yuan, reflecting a growth of 35.9% [8][9]. - The earnings per share (EPS) estimates for 2024, 2025, and 2026 are 0.97 yuan, 1.25 yuan, and 1.56 yuan, respectively [3][9]. - The target price is set at 29.10 yuan, based on a price-to-earnings (PE) ratio of 23 times for 2025 [3][4]. Market Data - The current stock price is 21.86 yuan, with a market capitalization of 8.879 billion yuan. The stock has traded within a range of 18.40 to 26.77 yuan over the past 52 weeks [5][6]. - The company has a net asset value per share of 5.58 yuan, with a price-to-book (P/B) ratio of 3.9 at the current price [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1]. Core Views - The company has demonstrated steady growth in revenue and profit, with the upcoming launch of Semaglutide expected to drive further growth. The small nucleic acid business is also entering a harvest phase, injecting new growth momentum [1]. - The company's revenue and profit growth in the first three quarters of 2024 is primarily attributed to the continued ramp-up of Dydrogesterone preparations and the recovery in demand for high-margin raw materials [1]. - The report anticipates that the company's performance will continue to maintain a steady growth trend due to the increasing volume of high-margin raw materials and the ongoing production ramp-up of Semaglutide and other peptide raw materials [1]. Financial Summary - **Revenue (in million CNY)**: - 2022A: 1008.08 (25.48% growth) - 2023A: 1262.53 (25.24% growth) - 2024E: 1528.23 (21.04% growth) - 2025E: 1873.56 (22.60% growth) - 2026E: 2287.04 (22.07% growth) [1]. - **Net Profit (in million CNY)**: - 2022A: 210.96 - 2023A: 289.42 - 2024E: 383.24 - 2025E: 500.91 - 2026E: 655.39 [1]. - **Earnings Per Share (in CNY)**: - 2022A: 0.52 - 2023A: 0.71 - 2024E: 0.94 - 2025E: 1.23 - 2026E: 1.61 [1]. - **Price-to-Earnings (P/E) Ratio**: - 2022A: 48.67 - 2023A: 35.48 - 2024E: 26.79 - 2025E: 20.50 - 2026E: 15.67 [1]. - **Price-to-Book (P/B) Ratio**: - 2022A: 6.13 - 2023A: 5.22 - 2024E: 4.48 - 2025E: 3.97 - 2026E: 3.46 [1]. Quarterly Performance - The company reported a revenue of 1.088 billion CNY in Q1-Q3 2024, representing a year-on-year growth of 17.97%. The net profit for the same period was 284 million CNY, with a year-on-year increase of 22.04% [1][2]. - The gross margin remained stable, and the increase in revenue led to a decrease in expense ratios, with continuous investment in R&D [1]. Future Outlook - The report suggests that the company is expected to continue its growth trajectory, driven by the ramp-up of Dydrogesterone tablets and a rich pipeline of projects, including the expansion of production capacity for peptides and small nucleic acid drugs [1].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 28.00, compared to the last closing price of 23.68 [1]. Core Views - The company's Q3 revenue and profit showed a slight decline quarter-on-quarter, but overall performance met market expectations. For Q3 2024, the company achieved revenue of 3.58 billion yuan, a decrease of 9.46% quarter-on-quarter, and a net profit of 0.95 billion yuan, an increase of 10.53% quarter-on-quarter [2][4]. - The year-to-date revenue for the first three quarters of 2024 reached 10.88 billion yuan, representing a year-on-year increase of 17.97%, while the net profit attributable to shareholders was 2.84 billion yuan, up 22.04% year-on-year [2][4]. - The decline in revenue and profit is attributed to a decrease in trade sales and an increase in financial expenses due to foreign exchange losses and convertible bond costs [2][4]. - The gross margin for Q3 2024 was 60.68%, down 3.69 percentage points year-on-year, while the net profit margin was 26.62%, down 10.12 percentage points year-on-year [2][4]. Summary by Sections Financial Performance - For Q3 2024, the company reported a revenue of 3.58 billion yuan and a net profit of 0.95 billion yuan, with a year-to-date revenue of 10.88 billion yuan and a net profit of 2.84 billion yuan [2][4]. - The company forecasts revenues of 15.38 billion yuan, 18.50 billion yuan, and 22.73 billion yuan for 2024, 2025, and 2026 respectively, with net profits of 3.91 billion yuan, 5.08 billion yuan, and 6.60 billion yuan for the same years [2][4]. Business Development - The company is actively promoting an integrated model of "active pharmaceutical ingredients + formulations," with the Dydrogesterone tablet expected to accelerate sales growth. The product was approved for sale in June 2023 and has been listed in 30 provinces and cities, with sales revenue of 92.48 million yuan in H1 2024 [2][4]. - The company has submitted registration applications for additional products, expecting to receive approvals for 3-5 new products annually starting in 2026 [2][4]. Valuation Metrics - The report provides projected earnings per share (EPS) of 0.96 yuan, 1.25 yuan, and 1.63 yuan for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings (PE) ratios of 25, 19, and 15 [2][4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10]. Core Views - The company has experienced rapid growth in the first three quarters of 2024, with a revenue of 1.088 billion yuan, representing a year-on-year increase of 17.97%. The net profit attributable to the parent company reached 284 million yuan, up 22.04% year-on-year, and the non-recurring net profit was 282 million yuan, reflecting a significant increase of 44.5% [3][4]. - The company's formulation business is expanding quickly, with the recent approval of various products expected to contribute to future growth. The company is enhancing its distribution network and academic team to improve market penetration [4][5]. - Due to significant export revenue and exchange rate fluctuations, the company's profit forecast has been adjusted downward for 2024-2026, with expected net profits of 391 million, 510 million, and 678 million yuan respectively [3][4]. Financial Summary - For the first three quarters of 2024, the company reported a gross margin of 58.22% (up 2.58 percentage points) and a net margin of 26.08% (up 0.85 percentage points) [3]. - The company's revenue and profit projections for the next few years indicate a strong growth trajectory, with expected revenues of 1.657 billion yuan in 2024, 2.184 billion yuan in 2025, and 2.710 billion yuan in 2026, reflecting year-on-year growth rates of 31.2%, 31.8%, and 24.1% respectively [6][7]. - The company's P/E ratios are projected to decrease from 24.6 in 2024 to 14.2 in 2026, indicating an attractive valuation as earnings grow [3][6].